HRP20210998T1 - Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met - Google Patents

Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met Download PDF

Info

Publication number
HRP20210998T1
HRP20210998T1 HRP20210998TT HRP20210998T HRP20210998T1 HR P20210998 T1 HRP20210998 T1 HR P20210998T1 HR P20210998T T HRP20210998T T HR P20210998TT HR P20210998 T HRP20210998 T HR P20210998T HR P20210998 T1 HRP20210998 T1 HR P20210998T1
Authority
HR
Croatia
Prior art keywords
cancer
met
treatment
mutation
met inhibitor
Prior art date
Application number
HRP20210998TT
Other languages
English (en)
Inventor
Melanie Mae Frigault
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20210998T1 publication Critical patent/HRP20210998T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)

Claims (10)

1. Inhibitor c-Met za uporabu u liječenju karcinoma, gdje je karcinom naznačen time što ima mutaciju MET 1195 i gdje je inhibitor c-Met savolitinib ili njegova farmaceutski prihvatljiva sol.
2. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 1, naznačen time što je mutacija MET 1195 supstitucija aminokiseline.
3. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 2, gdje je karcinom naznačen time što ima mutaciju MET L1195F.
4. Inhibitor c-Met za uporabu u liječenju karcinoma prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što je karcinom rak pluća, rak želuca ili papilarni karcinom bubrežnih stanica.
5. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 4, naznačen time što je karcinom papilarni karcinom bubrežnih stanica.
6. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 5, naznačen time što je karcinom papilarni karcinom bubrežnih stanica tipa II.
7. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 1, gdje je karcinom papilarni karcinom bubrežnih stanica tipa II koji je naznačen time što ima mutaciju MET L1195F, a savolitinib, ili njegova farmaceutski prihvatljiva sol, se primjenjuje u farmaceutskom pripravku koji sadrži 600 mg savolitiniba u obliku njegove slobodne baze, uz doziranje jednom dnevno.
8. Postupak pregleda pacijenata s karcinomom radi utvrđivanja njihove prikladnosti za liječenje inhibitorom c-Met, koji obuhvaća analizu reprezentativnog uzorka karcinoma pacijenta in-vitro kako bi se utvrdilo da li je karcinom naznačen time što ima mutaciju MET 1195, gdje ako se utvrdi da je karcinom kod pacijenta naznačen time što ima mutaciju MET 1195, pacijent je pogodan za liječenje inhibitorom c-Met, te gdje je inhibitor c-Met savolitinib ili njegova farmaceutski prihvatljiva sol.
9. Postupak prema patentnom zahtjevu 8, koji obuhvaća analizu reprezentativnog uzorka pacijentovog karcinoma in-vitro kako bi se utvrdilo da li je karcinom naznačen time što ima mutaciju MET L1195F, gdje ako se utvrdi da je karcinom kod pacijenta naznačen time što ima mutaciju MET L1195F, pacijent je pogodan za liječenje inhibitorom c-Met, te gdje je inhibitor c-Met savolitinib ili njegova farmaceutski prihvatljiva sol.
10. Postupak prema bilo kojem od patentnih zahtjeva 8 ili 9, naznačen time što je karcinom papilarni karcinom bubrežnih stanica.
HRP20210998TT 2016-09-22 2021-06-24 Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met HRP20210998T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1616116.8A GB201616116D0 (en) 2016-09-22 2016-09-22 Use of c-Met inhibitors to treat cancers harbouring MET mutations
PCT/EP2017/073894 WO2018055029A1 (en) 2016-09-22 2017-09-21 Use of c-met inhibitors to treat cancers harbouring met mutations
EP17777211.8A EP3515418B1 (en) 2016-09-22 2017-09-21 Use of c-met inhibitors to treat cancers harbouring met mutations

Publications (1)

Publication Number Publication Date
HRP20210998T1 true HRP20210998T1 (hr) 2021-09-17

Family

ID=57539720

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210998TT HRP20210998T1 (hr) 2016-09-22 2021-06-24 Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met

Country Status (17)

Country Link
US (1) US20190282570A1 (hr)
EP (1) EP3515418B1 (hr)
JP (1) JP7065858B2 (hr)
CN (1) CN109789108A (hr)
CY (1) CY1124668T1 (hr)
DK (1) DK3515418T3 (hr)
ES (1) ES2880085T3 (hr)
GB (1) GB201616116D0 (hr)
HR (1) HRP20210998T1 (hr)
HU (1) HUE054765T2 (hr)
LT (1) LT3515418T (hr)
PL (1) PL3515418T3 (hr)
PT (1) PT3515418T (hr)
RS (1) RS62084B1 (hr)
SI (1) SI3515418T1 (hr)
TW (1) TWI784969B (hr)
WO (1) WO2018055029A1 (hr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020100969A1 (ja) * 2018-11-14 2021-12-02 学校法人金沢医科大学 びまん性胃がんを治療するための医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
SI1959955T1 (sl) * 2005-12-05 2011-02-28 Pfizer Prod Inc Postopek zdravljenja abnormalne celične rasti
EP2004693B1 (en) * 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met
CN106432225B (zh) 2009-12-31 2019-02-19 和记黄埔医药（上海）有限公司 某些三唑并吡啶化合物和三唑并吡嗪化合物、其组合物和其使用方法

Also Published As

Publication number Publication date
RS62084B1 (sr) 2021-08-31
EP3515418A1 (en) 2019-07-31
LT3515418T (lt) 2021-07-26
EP3515418B1 (en) 2021-04-14
TWI784969B (zh) 2022-12-01
CN109789108A (zh) 2019-05-21
DK3515418T3 (da) 2021-07-12
PL3515418T3 (pl) 2021-12-13
JP7065858B2 (ja) 2022-05-12
PT3515418T (pt) 2021-07-13
JP2019529554A (ja) 2019-10-17
TW201909916A (zh) 2019-03-16
GB201616116D0 (en) 2016-11-09
WO2018055029A1 (en) 2018-03-29
SI3515418T1 (sl) 2021-08-31
US20190282570A1 (en) 2019-09-19
HUE054765T2 (hu) 2021-09-28
CY1124668T1 (el) 2022-07-22
ES2880085T3 (es) 2021-11-23

Similar Documents

Publication Publication Date Title
EP3222278B1 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
Wang et al. A review on curability of cancers: more efforts for novel therapeutic options are needed
Tan et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
Yap et al. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
Saka et al. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
Grippo et al. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma
JP2019532051A5 (hr)
BR112016011078A8 (pt) derivados de 1-(5-terc-butil-2-arilpirazol-3-il)-3-[2-flúor-4-[(3-oxo-4h-pirido[2,3-b]pirazin-8- il)óxi]fenil]ureia, seus usos, sua composição farmacêutica, método para preparar a mesma e método in vitro para inibir a função raf em uma célula
HRP20221316T1 (hr) Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju
Nakano et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile
Blomberg et al. Randomized trials of systemic medically-treated malignant mesothelioma: a systematic review
Swain et al. Design and characterization of enteric-coated controlled release mucoadhesive microcapsules of rabeprazole sodium
HRP20210998T1 (hr) Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met
Schmidt et al. Targeting protein synthesis in colorectal cancer
JP2014525454A5 (hr)
Malakar et al. Theophylline release behavior from hard gelatin capsules containing hydrophilic polymeric matrices.
Van Wynsberghe et al. Nephrotoxicity of anti-angiogenic therapies
HRP20151186T1 (hr) Farmaceutska kombinacija
Kacan et al. Antitumor activity of sorafenib on colorectal cancer
Asahina et al. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
CN104138380B (zh) 厄洛替尼或其可药用盐的组合物及其制备方法和用途
EA201990129A1 (ru) Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона
Mishima et al. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study)
JP2019529554A5 (hr)